25 October 2012 08:21 [Source: ICIS news]
SINGAPORE (ICIS)--Novartis reported a 5% year-on-year decline in its third quarter net income to $3.9bn (€3bn), , due partly on the appreciation of the US dollar, the Swiss pharmaceuticals company said on Thursday.
Sales for the third quarter fell by 7% year on year to $13.8bn, Novartis said in a statement.
Novartis’ operating income for the third quarter rose by 3% to $3.03bn, the statement added.
“While Novartis net sales were impacted by the patent expiration of Diovan and a down quarter in Sandoz and Consumer Health, our launch brands performed well and now represent 29% of Group sales. Pharmaceuticals had another solid quarter,” said Jopseph Jimenez, CEO of Novartis.
($1 = €0.77)
For the latest chemical news, data and analysis that directly impacts your business sign up for a free trial to ICIS news - the breaking online news service for the global chemical industry.
Get the facts and analysis behind the headlines from our market leading weekly magazine: sign up to a free trial to ICIS Chemical Business.
|ICIS news FREE TRIAL|
|Get access to breaking chemical news as it happens.|
|ICIS Global Petrochemical Index (IPEX)|
|ICIS Global Petrochemical Index (IPEX). Download the free tabular data and a chart of the historical index|
Asian Chemical Connections